Data / Drug companies / Patheon Manufacturing Services LLC
Patheon Manufacturing Services LLC: 92 products in the FDA NDC directory, labeler code 63552
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Patheon Manufacturing Services LLC (labeler code 63552) lists 92 products in the FDA National Drug Code Directory. By type: 90 drugs for further processing, 2 vaccines. Its main marketing category is drugs for further processing. The newest product started marketing on September 4, 2026.
The request: Watch Patheon Manufacturing Services LLC (FDA labeler code 63552): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 63552
- Products in commercial distribution
- 92
- Packages
- 106
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule II 11, Schedule IV 2
- Started marketing in the last 12 months
- 4
- Products with a marketing end date set
- 5
- Earliest marketing start
- January 10, 1967
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 91 | 98.9% |
| Biologics (BLA) | 1 | 1.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 90 | 97.8% |
| Vaccines | 2 | 2.2% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 21 | 22.8% |
| Tablet | 15 | 16.3% |
| Injection, powder, lyophilized, for solution | 14 | 15.2% |
| Injection, solution | 10 | 10.9% |
| Capsule | 8 | 8.7% |
| Solution | 4 | 4.3% |
| Tablet, extended release | 4 | 4.3% |
| Tablet, film coated | 3 | 3.3% |
| Injection, solution, concentrate | 2 | 2.2% |
| Tablet, film coated, extended release | 2 | 2.2% |
| Injection, powder, for solution | 2 | 2.2% |
| Injection, suspension | 2 | 2.2% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Camizestrant | 63552-290 | Tablet, film coated | Drugs for further processing | September 4, 2026 |
| Water | 63552-287 | Injection | Drugs for further processing | January 14, 2026 |
| Water | 63552-286 | Injection | Drugs for further processing | January 14, 2026 |
| Ephedrine sulfate | 63552-282 | Injection | Drugs for further processing | December 23, 2025 |
| Ixekizumab | 63552-280 | Injection, solution | Drugs for further processing | October 23, 2025 |
| Plerixafor | 63552-725 | Injection, solution | Drugs for further processing | September 1, 2025 |
| Nirsevimab | 63552-724 | Injection | Drugs for further processing | September 1, 2025 |
| Nirsevimab | 63552-723 | Injection | Drugs for further processing | September 1, 2025 |
| Fluzone high dose northern hemisphere | 63552-722 | Injection, suspension | Biologics (BLA) | September 1, 2025 |
| Clesrovimab | 63552-269 | Injection, solution | Drugs for further processing | June 9, 2025 |
| .alpha.1-proteinase inhibitor human | 63552-213 | Injection | Drugs for further processing | January 17, 2025 |
| .alpha.1-proteinase inhibitor human | 63552-210 | Injection | Drugs for further processing | January 17, 2025 |
| Human papillomavirus quadrivalent (types 6, 11, 16, and 18) | 63552-212 | Injection, suspension | Drugs for further processing | December 23, 2024 |
| Foscarbidopa/foslevodopa | 63552-215 | Injection | Drugs for further processing | October 17, 2024 |
| Aflibercept-jbvf | 63552-281 | Injection | Drugs for further processing | May 20, 2024 |
| Naxitamab | 63552-209 | Injection | Drugs for further processing | November 7, 2023 |
| Asparaginase erwinia chrysanthemi (recombinant)-rywn | 63552-285 | Injection | Drugs for further processing | October 31, 2023 |
| Talquetamab | 63552-199 | Injection | Drugs for further processing | August 9, 2023 |
| Nirsevimab | 63552-208 | Injection | Drugs for further processing | July 18, 2023 |
| Nirsevimab | 63552-207 | Injection | Drugs for further processing | July 18, 2023 |
| Teclistamab | 63552-198 | Injection | Drugs for further processing | October 25, 2022 |
| Teclistamab | 63552-197 | Injection | Drugs for further processing | October 25, 2022 |
| Trastuzumab-anns | 63552-270 | Injection, powder, lyophilized, for solution | Drugs for further processing | August 2, 2022 |
| Tecovirimat | 63552-193 | Injection, solution, concentrate | Drugs for further processing | May 31, 2022 |
| Semaglutide | 63552-206 | Injection, solution | Drugs for further processing | June 5, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.